1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Bayer supporting GARFIELD, an atrial fibrillation registry

 
• By John Davis

A research grant from Bayer Schering Pharma is supporting GARFIELD (the global anticoagulant registry in the field), the first-ever global atrial fibrillation registry. It will follow, for six years, 50,000 patients from 32 countries who are newly diagnosed with atrial fibrillation. GARFIELD is the first prospective registry in the condition; clinical sites will be selected at random to avoid selection bias, and patients included whether or not they receive anticoagulant therapy. The study is being conducted by the Thrombosis Research Institute, which is affiliated with Queen Mary University of London.

A research grant from Bayer Schering Pharma is supporting GARFIELD (the global anticoagulant registry in the field), the first-ever global atrial fibrillation registry. It will follow, for six years, 50,000 patients from 32 countries who are newly diagnosed with atrial fibrillation. GARFIELD is the first prospective registry in the condition; clinical sites will be selected at random to avoid selection bias, and patients included whether or not they receive anticoagulant therapy. The study is being conducted by the Thrombosis Research Institute, which is affiliated with Queen Mary University of London.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve

 
• By Joseph Haas

Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.

Merck & Co.’s Enlicitide Poised To Be First Oral PCSK9 Inhibitor To Market

 
• By Jessica Merrill

The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

More from Therapeutic Category

Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve

 
• By Joseph Haas

Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.

Enliven Raises $230m To Fund Scemblix Leukemia Challenger

 
• By Andrew McConaghie

The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.

Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death

 
• By Joseph Haas

With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.